Page 6 - Efavirenz WHO PQ: A case study of a public-private collaboration

ทุนสนับสนุนงานวิจัยจากสถาบันวิจัยระบบสาธารณสุข (สวรส.) | จ

ABSTRACT

Background: Technology transfer involved the transfer of knowledge and technical
know-how, as well as physical devices and equipment. There have been several factors

influencing success.

Objective: This study aimed to draw the lesson learned from the Government
Pharmaceutical Organization (GPO) and Mylan technology transferring to achieve

accreditation by the WHO Prequalification Programme (WHO PQ).

Methods: Qualitative research was used. The information was collected by studying
the documents published officially and non-officially, and in-depth interviews were

conducted with selected key informants relevant to this technology transfer. Then a

content analysis was performed.
Results: GPO has inherited technology from Mylan, India's leading generic company.

Until GPO can produce and control the quality of antiretroviral drugs Efavirenz and

certified by the World Health Organization. The important conclusions of this study
were as follows 1) The important policy decisions included the policy that impels GPO

to be accredited by WHO PQ and the one that GPO decided to collaborate with the

Mylan. 2) The success factor was the good relationship between the technology
transferor (Mylan) and the technology transferee (GPO). This relationship motivated the

intent teamwork between GPO and the Mylan in production as well as quality control

that led to accreditation by WHO PQ. The country's supporting factors included the
universal health coverage policy, the support of AIDS problem solving by producing

HIV antiretroviral drugs in the country, GPO's capacity, and implementing the

‘Sustainable Potential Development Plan in Thailand, Section: WHO Pre-qualification
Scheme ’in B.E. 2554. The international context also contributed. For instance, WHO

has the Global Fund's approval to support the developing countries with a

pharmaceutical production capacity in terms of technical assistance. So those
countries can enhance the quality to the level recognized to provide antiretroviral

drugs for the projects in several countries in which the procurement can be made
using the Global Fund budget. 3) The obstacles that made GPO spent over 17 years to